CoreCap Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

CoreCap Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$9	–	2809
2025 Q2	$9	Hold	8	–	–	﹤0.01%	2743
2025 Q1	$10	Hold	8	–	–	﹤0.01%	3119
2024 Q4	$18	Buy	+8	New	+$15	﹤0.01%	2821
2024 Q2	–	Sell	-9	Closed	-$75	–	1697
2024 Q1	$75	Buy	+9	New	+$49	﹤0.01%	2459
2022 Q4	$218	Buy	+9	New	+$336	﹤0.01%	2264
2022 Q3	–	Sell	-9	Closed	–	–	675
2022 Q2	$0	Buy	+9	New	+$405	﹤0.01%	2128
2022 Q1	–	Sell	-9	Closed	-$1K	–	686
2021 Q4	$1K	Buy	+9	New	+$443	﹤0.01%	2051

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

CoreCap Advisors's BCLI Position: Q3 2025 in Review

CoreCap Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 8 shares — an estimated $9 sold.

CoreCap Advisors first reported a position in BCLI in Q4 2021 and held it in 7 quarters. The position peaked at $1K in Q4 2021. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

CoreCap Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
CoreCap Advisors sold 8 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $9.
CoreCap Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2021 and held it in 7 quarters.
CoreCap Advisors's BRAINSTORM CELL THERAPUTC position peaked at $1K in Q4 2021.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on CoreCap Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.